Sign In
Buy OTLK
$1.61
-0.0700 (-4.17%)
At Close: Jun 25, 2026
OTLK Stock Up 35% as FDA Accepts Resubmitted Eye Drug BLA for Review
11:21am, Wednesday, 17'th Jun 2026
Outlook Therapeutics stock surges 35% after the FDA accepts the resubmitted Lytenava BLA for wet AMD for review, setting a July 29, 2026, decision date.
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
08:39am, Wednesday, 17'th Jun 2026
Outlook Therapeutics Inc. (NASDAQ:OTLK) shares are rising in Wednesday premarket trading after the company announced the FDA accepted its resubmitted Biologics License Application (BLA) for ONS-5010/L
ISELIN, N. J. , June 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of
Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity
08:55am, Saturday, 06'th Jun 2026
Outlook Therapeutics receives a buy rating due to a recent FDA appeal victory, improving the probability of US approval for Lytenava. OTLK's near-term upside is driven by regulatory catalysts, despite
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevaciz
Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04:00pm, Thursday, 28'th May 2026
ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizu
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA
09:16am, Tuesday, 26'th May 2026
Outlook Therapeutics, Inc. (NASDAQ:OTLK) shares are trading higher Tuesday after the company announced that the U.S. Food and Drug Administration granted its appeal following the Formal Dispute Resolu
Outlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
07:00am, Tuesday, 26'th May 2026
ISELIN, N.J., May 26, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizu
Oncobiologics, Inc. (OTLK) Reports Q2 Loss, Lags Revenue Estimates
06:25pm, Friday, 15'th May 2026
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.4 per share a year ago.
Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
04:05pm, Friday, 15'th May 2026
ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of ret
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
04:05pm, Thursday, 23'rd Apr 2026
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the stand
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
08:30am, Wednesday, 22'nd Apr 2026
ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the stand
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
09:05am, Tuesday, 21'st Apr 2026
ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
08:50am, Tuesday, 07'th Apr 2026
ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
04:05pm, Wednesday, 25'th Mar 2026
ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r
